CD8+ T cells in Leishmania infections: Friends or foes?

Frontiers in Immunology

Volumn 3, Issue JAN, 2012, Pages

  Stäger, Simona ^a   Rafati, Sima ^b  

^a UNIVERSITÉ LAVAL   (Canada)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

CD8T cells; Immunology; Leishmania

Indexed keywords

EID: 84874143982     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2012.00005     Document Type: Review

References (99)

1. Ahmed, S., Colmenares, M., Soong, L., Goldsmith-Pestana, K., Munstermann, L., Molina, R., and Mcmahon-Pratt, D. (2003). Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis. Infect. Immun. 71, 401-410.
2. Alexander, C. E., Kaye, P. M., and Engwerda, C. R. (2001). CD95 is required for the early control of parasite burden in the liver of Leishmania donovani-infected mice. Eur. J. Immunol. 31, 1199-1210.
3. Badovinac, V. P., Haring, J. S., and Harty, J. T. (2007). Initial T cell receptor transgenic cell precursor frequency dictates critical aspects of the CD8(+)Tcell response to infection. Immunity 26, 827-841.
4. Barral-Netto, M., Barral, A., Brodskyn, C., Carvalho, E. M., and Reed, S. G. (1995). Cytotoxicity in human mucosal and cutaneous leishmaniasis. Parasite Immunol. 17, 21-28.
5. Basu, R., Roy, S., and Walden, P. (2007). HLA class I-restricted T cell epitopes of the kinetoplastid membrane protein-11 presented by Leishmania donovani-infected human macrophages. J. Infect. Dis. 195, 1373-1380.
6. Belkaid, Y., Von Stebut, E., Mendez, S., Lira, R., Caler, E., Bertholet, S., Udey, M. C., and Sacks, D. (2002). CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J. Immunol. 168, 3992-4000.
7. Bertholet, S., Goldszmid, R., Morrot, A., Debrabant, A., Afrin, F., Collazo Custodio, C., Houde, M., Desjardins, M., Sher, A., and Sacks, D. (2006). Leishmania antigens are presented to CD8+ T cells by a transporter associated with antigen processing independent pathway in vitro and in vivo. J. Immunol. 177, 3525-3533.
8. Boaventura, V. S., Santos, C. S., Cardoso, C. R., De Andrade, J., Dos Santos, W. L., Clarencio, J., Silva, J. S., Borges, V. M., Barral-Netto, M., Brodskyn, C. I., and Barral, A. (2010). Human mucosal leishmaniasis: neutrophils infiltrate areas of tissue damage that express high levels of Th17-related cytokines. Eur. J. Immunol. 40, 2830-2836.
9. Bottrel, R. L., Dutra, W. O., Martins, F. A., Gontijo, B., Carvalho, E., Barral-Netto, M., Barral, A., Almeida, R. P., Mayrink, W., Locksley, R., and Gollob, K. J. (2001). Flow cytometric determination of cellular sources and frequencies of key cytokine-producing lymphocytes directed against recombinant LACK and soluble Leishmania antigen in human cutaneous leishmaniasis. Infect. Immun. 69, 3232-3239.
10. Bourreau, E., Ronet, C., Couppie, P., Sainte-Marie, D., Tacchini-Cottier, F., and Launois, P. (2007). IL-10 producing CD8+ T cells in human infection with Leishmania guyanensis. Microbes Infect. 9, 1034-1041.
11. Bousoffara, T., Louzir, H., Ben Salah, A., and Dellagi, K. (2004). Analysis of granzyme B activity as a surrogate marker of Leishmania-specific cellmediated cytotoxicity in zoonotic cutaneous leishmaniasis. J. Infect. Dis. 189, 1265-1273.
12. Brodskyn, C. I., Barral, A., Boaventura, V., Carvalho, E., and Barral-Netto, M. (1997). Parasite-driven in vitro human lymphocyte cytotoxicity against autologous infected macrophages from mucosal leishmaniasis. J. Immunol. 159, 4467-4473.
13. Bunting, M., Harris, E. S., Mcintyre, T. M., Prescott, S. M., and Zimmerman, G. A. (2002). Leukocyte adhesion deficiency syndromes: adhesion and tethering defects involving beta 2 integrins and selectin ligands. Curr. Opin. Hematol. 9, 30-35.
14. Campos-Neto,A., Porrozzi, R., Greeson, K., Coler, R. N., Webb, J. R., Seiky, Y. A., Reed, S. G., and Grimaldi, G. Jr. (2001). Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect. Immun. 69, 4103-4108.
15. Canaday, D. H., Wilkinson, R. J., Li, Q., Harding, C. V., Silver, R. F., and Boom, W. H. (2001). CD4(+) and CD8(+) T cells kill intracellular Mycobacterium tuberculosis by a perforin and Fas/Fas ligand-independent mechanism. J. Immunol. 167, 2734-2742.
16. Chakravarty, J., Kumar, S., Trivedi, S., Rai, V. K., Singh, A., Ashman, J. A., Laughlin, E. M., Coler, R. N., Kahn, S. J., Beckmann, A. M., Cowgill, K. D.,Reed,S. G.,Sundar,S.,and Piazza, F. M. (2011). A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine 29, 3531-3537.
17. Clarencio, J., De Oliveira, C. I., Favali, C., Medina, O., Caldas, A., Costa, C. H., Costa, D. L., Brodskyn, C., Barral, A., and Barral-Netto, M. (2009). Could the lower frequency of CD8+CD18+CD45RO+ lymphocytes be biomarkers of human VL? Int. Immunol. 21, 137-144.
18. Coler, R. N., Skeiky, Y. A., Bernards, K., Greeson, K., Carter, D., Cornellison, C. D., Modabber, F., Campos-Neto, A., and Reed, S. G. (2002). Immunization with a polyprotein vaccine consisting of the T-cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect. Immun. 70,4215-4225.
19. Colmenares, M., Kima, P. E., Samoff, E., Soong, L., and Mcmahon-Pratt, D. (2003). Perforin and gamma interferon are critical CD8+ Tcell-mediated responses in vaccine induced immunity against Leishmania amazonensis infection. Infect. Immun. 71, 3172-3182.
20. Da Conceicao-Silva, F., Perlaza, B. L., Louis, J. A., and Romero, P. (1994). Leishmania major infection in mice primes for specific major histocom patibility complex class I-restricted CD8+ cytotoxic T cell responses. Eur. J. Immunol. 24, 2813-2817.
21. Da-Cruz, A. M., Bertho, A. L., Oliveira Neto, M. P., and Coutinho, S. G. (2005). Flow cytometric analysis of cellular infiltrate from American tegumentary leishmaniasis lesions. Br. J. Dermatol. 153, 537-543.
22. Da-Cruz, A. M., Bittar, R., Mattos, M., Oliveira-Neto, M. P., Nogueira, R., Pinho-Ribeiro, V., Azeredo Coutinho, R. B., and Coutinho, S. G. (2002). T-cell-mediated immune responses in patients with cutaneous or mucosal leishmaniasis: long-term evaluation after therapy. Clin. Diagn. Lab. Immunol. 9, 251-256.
23. Da-Cruz, A. M., Conceicao-Silva, F., Bertho, A. L., and Coutinho, S. G. (1994). Leishmania-reactive CD4+ and CD8+ T cells associated with cure of human cutaneous leishmaniasis. Infect. Immun. 62,2614-2618.
24. Dumonteil, E. (2009). Vaccine development against Trypanosoma cruzi and Leishmania species in the postgenomic era. Infect.Genet.Evol.9, 1075-1082.
25. Ellner, J. J., Olds, G. R., Lee, C. W., Kleinhenz, M. E., and Edmonds, K. L. (1982). Destruction of the multicellular parasite Schistosoma mansoni byTlymphocytes.J. Clin. Invest. 70, 369-378.
26. Farajnia, S., Mahboudi, F., Ajdari, S., Reiner, N. E., Kariminia, A., and Alimohammadian, M. H. (2005). Mononuclear cells from patients recovered from cutaneous leishmaniasis respond to Leishmania major amastigote class I nuclease with a predominant Th1-like response. Clin. Exp. Immunol. 139, 498-505.
27. Faria, D. R., Souza, P. E., Duraes, F. V., Carvalho, E. M., Gollob, K. J., Machado, P. R., and Dutra, W. O. (2009). Recruitment of CD8(+) T cells expressing granzyme A is associated with lesion progression in human cutaneous leishmaniasis. Parasite Immunol. 31, 432-439.
28. Gaafar, A., Veress, B., Permin, H., Kharazmi, A., Theander, T. G., and El Hassan, A. M. (1999). Characterization of the local and systemic immune responses in patients with cutaneous leishmaniasis due to Leishmania major. Clin. Immunol. 91, 314-320.
29. Ganguly, S., Das, N. K., Panja, M., Pal, S., Modak, D., Rahaman, M., Mallik, S., Guha, S. K., Pramanik, N., Goswami, R., Barbhuiya, J. N., Saha, B., and Chatterjee, M. (2008). Increased levels of interleukin-10 and IgG3 are hallmarks of Indian post-kala-azar dermal leishmaniasis. J. Infect. Dis. 197, 1762-1771.
30. Garcia, M. R., Graham, S., Harris, R. A., Beverley, S. M., and Kaye, P. M. (1997). Epitope cleavage by Leishmania endopeptidase(s) limits the efficiency of the exogenous pathway of major histocompatibility complex class I-associated antigen presentation. Eur. J. Immunol. 27,1005-1013.
31. Gaze, S. T., Dutra, W. O., Lessa, M., Lessa, H., Guimaraes, L. H., Jesus, A. R., Carvalho, L. P., Machado, P., Carvalho,E. M.,and Gollob,K. J. (2006). Mucosal leishmaniasis patients display an activated inflammatory Tcell phenotype associated with a nonbalanced monocyte population. Scand. J. Immunol. 63, 70-78.
32. Grimaldi, G. J. (1995). Meetings on vaccine studies towards the control of leishmaniasis. Curr. Opin. Immunol. 4, 413-418.
33. Guerfali, F. Z., Ben-Abdallah, H., Sghaier, R. M., Ben-Aissa, K., Mkannez, G., Attia, H., and Laouini, D. (2009). An in silico immunological approach for prediction of CD8+ T cell epitopes of Leishmania major proteins in susceptible BALB/c and resistant C57BL/6 murine models of infection. Infect.Genet.Evol.9, 344-350.
34. Hailu, A., Van Baarle, D., Knol, G. J., Berhe, N., Miedema, F., and Kager, P. A. (2005). T cell subset and cytokine profiles in human visceral leishmaniasis during active and asymptomatic or sub-clinical infection with Leishmania donovani. Clin. Immunol. 117, 182-191.
35. Harty, J. T., and Badovinac, V. P. (2008). Shaping and reshaping CD8+ Tcell memory. Nat. Rev. Immunol. 8, 107-119.
36. Herath, S., Kropf, P., and Muller, I. (2003). Cross-talk between CD8(+) and CD4(+) T cells in experimental cutaneous leishmaniasis: CD8(+)T cells are required for optimal IFN-gamma production by CD4(+)T cells. Parasite Immunol. 25, 559-567.
37. Hernandez-Ruiz, J., Salaiza-Suazo, N., Carrada, G., Escoto, S., Ruiz Remigio, A., Rosenstein, Y., Zentella, A., and Becker, I. (2010). CD8 cells of patients with diffuse cutaneous leishmaniasis display functional exhaustion: the latter is reversed, in vitro, by TLR2 agonists. PLoS Negl. Trop. Dis. 4, e871. doi:10.1371/journal.pntd.0000871.
38. Hill, J. O., Awwad, M., and North, R. J. (1989). Elimination of CD4+ suppressor T cells from susceptible BALB/c mice releases CD8+ T lymphocytes to mediate protective immunity against Leishmania. J. Exp. Med. 169, 1819-1827.
39. Huber, M., Timms, E., Mak, T. W., Rollinghoff, M., and Lohoff, M. (1998). Effective and longlasting immunity against the parasite Leishmania major in CD8 deficient mice. Infect. Immun. 66, 3968-3970.
40. Iborra, S., Soto, M., Carrion, J., Alonso, C., and Requena, J. M. (2004). Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis. Vaccine 22, 3865-3876.
41. Jordan, K. A., and Hunter, C. A. (2010). Regulation of CD8+ Tcell responses to infection with parasitic protozoa. Exp. Parasitol. 126, 318-325.
42. Joshi, T., Rodriguez, S., Perovic, V., Cockburn, I. A., and Stager, S. (2009). B7-H1 blockade increases survival of dysfunctional CD8(+) T cells and confers protection against Leishmania donovani infections. PLoS Pathog. 5, e1000431. doi:10.1371/journal.ppat.1000431.
43. Kaech, S. M., Wherry, E. J., and Ahmed, R. (2002). Effector and memory T-cell differentiation: implications for vaccine development. Nat. Rev. Immunol. 2, 251-262.
44. Kaye, P. M., Cooke, A., Lund, T., Wattie, M., and Blackwell, J. M. (1992). Altered course of visceral leishmaniasis in mice expressing transgenic I-E molecules. Eur. J. Immunol. 22, 357-364.
45. Khalil, E. A., El Hassan, A. M., Zijlstra, E. E., Mukhtar, M. M., Ghalib, H. W., Musa, B., Ibrahim, M. E., Kamil, A. A., Elsheikh, M., Babiker, A., and Modabber, F. (2000). Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG controlled trial in Sudan. Lancet 356, 1565-1569.
46. Khan, I. A., Smith, K. A., and Kasper, L. H. (1990). Induction of antigenspecific human cytotoxic T cells by Toxoplasma gondii. J. Clin. Invest. 85, 1879-1886.
47. Kima, P. E., Ruddle, N. H., and Mcmahon-Pratt, D. (1997). Presentation via the class I pathway by Leishmania amazonensis infected macrophages of an endogenous leishmanial antigen to CD8+ T cells. J. Immunol. 159, 1828-1834.
48. Llanos-Cuentas, A., Calderón, W., Cruz, M., Ashman, J. A., Alves, F. P., Coler, R. N., Bogatzki, L.Y., Bertholet, S., Laughlin, E. M., Kahn, S. J., Beckmann, A. M., Cowgill, K. D., Reed, S. G., and Piazza, F. M. (2010). A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis. Vaccine 28, 7427-7435.
49. Louis, J., Himmelrich, H., Parra-Lopez, C., Tacchini-Cottier, F., and Launois, P. (1998). Regulation of protective immunity against Leishmania major in mice. Curr. Opin. Immunol. 10, 459-464.
50. Mackay, C. R. (2001). Chemokines: immunologys high impact factors. Nat. Immunol. 2, 95-101.
51. Martin, S., Pahari, S., Sudan, R., and Saha, B. (2010). CD40 signaling in CD8 + CD40+ T cells turns on contra-T regulatory cell functions. J. Immunol. 184, 5510-5518.
52. Mary, C., Auriault, V., Faugere, B., and Dessein, A. J. (1999). Control of Leishmania infantum infection is associated with CD8(+) and gamma interferon and interleukin-5-producing CD4(+) antigen-specific T cells. Infect. Immun. 67, 5559-5566.
53. Mendez, S., Belkaid, Y., Seder, R. A., and Sacks, D. (2002). Optimization of DNA vaccination against cutaneous leishmaniasis. Vaccine 20, 3702-3708.
54. Modabber, F. (1990). Development of vaccines against leishmaniasis. Scand. J. Infect. Dis. Suppl. 76, 72-78.
55. Mohajery, M. (2007). Tc1 Cells percentage in patients with cutaneous leishmaniasis before and after treatment with Glucantime. Iran. J. Public Health 36, 55-61.
56. Momeni, A. Z., Jalayer, T., Emamjomeh, M., Khamesipour, A., Zicker, F., Ghassemi, R. L., Dowlati, Y., Sharifi, I., Aminjavaheri, M., Shafiei, A., Alimohammadian, M. H., Hashemi Fesharki, R., Nasseri, K., Godal, T., Smith, P. G., and Modabber, F. (1999). A randomised, doubleblind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine 17, 466-472.
57. Mueller, S. N., and Ahmed, R. (2009). High antigen levels are the cause of T cell exhaustion during chronic viral infection. Proc. Natl. Acad. Sci. U.S.A. 106, 8623-8628.
58. Muller, I., Kropf, P., Etges, R. J., and Louis, J. A. (1993). Gamma interferon response in secondary Leishmania major infection: role of CD8+ T cells. Infect. Immun. 61, 3730-3738.
59. Muller, I., Kropf, P., Louis, J. A., and Milon, G. (1994). Expansion of gamma interferon-producing CD8+ T cells following secondary infection of mice immune to Leishmania major. Infect. Immun. 62, 2575-2581.
60. Muller, I., Pedrazzini, T., Kropf, P., Louis, J., and Milon, G. (1991). Establishment of resistance to Leishmania major infection in susceptible BALB/c mice requires parasite specific CD8+ T cells. Int. Immunol. 3, 587-597.
61. Narni-Mancinelli, E., Campisi, L., Bassand, D., Cazareth, J., Gounon, P., Glaichenhaus, N., and Lauvau, G. (2007). Memory CD8+ T cells mediate antibacterial immunity via CCL3 activation of TNF/ROI+ phagocytes. J. Exp. Med. 204, 2075-2087.
62. Nateghi Rostami, M., Keshavarz, H., Edalat, R., Sarrafnejad, A., Shahrestani, T., Mahboudi, F., and Khamesipour, A. (2010). CD8+ T cells as a source of IFN-gamma production in human cutaneous leishmaniasis. PLoS Negl. Trop. Dis. 4, e845. doi:10.1371/journal.pntd.0000845.
63. Palmer, E. M., Holbrook, B. C., Arimilli, S., Parks, G. D., and Alexander-Miller, M. A. (2010). IFNgamma-producing, virusspecific CD8+ effector cells acquire the ability to produce IL-10 as a result of entry into the infected lung environment. Virology 404, 225-230.
64. Polley, R., Stager, S., Prickett, S., Maroof, A., Zubairi, S., Smith, D. F., and Kaye, P. M. (2006). Adoptive immunotherapy against experimental visceral leishmaniasis with CD8+ Tcells requires the presence of cognate antigen. Infect. Immun. 74, 773-776.
65. Rafati, S., Kariminia, A., Seyde-Eslami, S., Narimani, M., Taheri, T., and Lebbatard, M. (2002). Recombinant cysteine proteinases-based vaccines against Leishmania major in BALB/c mice: the partial protection relies on interferon gamma producing CD8(+) T lymphocyte activation. Vaccine 20, 2439-2447.
66. Rafati, S., Salmanian, A. H., Taheri, T., Vafa, M., and Fasel, N. (2001). A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major. Vaccine 19, 3369-3375.
67. Reiner, S. L., and Locksley, R. M. (1995). The regulation of immunity to Leishmania major. Annu. Rev. Immunol. 13, 151-177.
68. Resende, D. M., Caetano, B. C., Dutra, M. S., Penido, M. L., Abrantes, C. F., Verly, R. M., Resende, J. M., Pilo-Veloso, D., Rezende, S. A., Bruna-Romero, O., Fernandes, A. P., and Gazzinelli, R. T. (2008). Epitope mapping and protective immunity elicited by adenovirus expressing the Leishmania amastigote specific A2 antigen: correlation with IFN-gamma and cytolytic activity by CD8+ T cells. Vaccine 26, 4585-4593.
69. Robinson, H. L., and Amara, R. R. (2005). T cell vaccines for microbial infections. Nat. Med. 11, S25-S32.
70. Rogers, K. A., and Titus, R. G. (2004). Characterization of the early cellular immune response to Leishmania major using peripheral blood mononuclear cells from Leishmania-naive humans. Am. J. Trop. Med. Hyg. 71, 568-576.
71. Russo, D. M., Chakrabarti, P., and Higgins, A. Y. (1999). Leishmania: naive human T cells sensitized with promastigote antigen and IL-12 develop into potent Th1 and CD8(+)cytotoxic effectors. Exp. Parasitol. 93, 161-170.
72. Sacks, D., and Noben-Trauth, N. (2002). The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol. 2, 845-858.
73. Salaiza-Suazo, N., Volkow, P., Tamayo, R., Moll, H., Gillitzer, R., PerezTorres, A., Perez-Montfort, R., Dominguez,J. D.,Velasco-Castrejon, O., Crippa, M., and Becker, I. (1999). Treatment of two patients with diffuse cutaneous leishmaniasis caused by Leishmania mexicana modifies the immunohistological profile but not the disease outcome. Trop. Med. Int. Health 4, 801-811.
74. Salata, R. A., Cox, J. G., and Ravdin, J. I. (1987). The interaction of human T-lymphocytes and Entamoeba histolytica: killing of virulent amoebae by lectin-dependent lymphocytes. Parasite Immunol. 9, 249-261.
75. Sanchez, M. A., Diaz, N. L., Zerpa, O., Negron, E., Convit, J., and Tapia, F. J. (2004). Organ-specific immunity in canine visceral leishmaniasis: analysis of symptomatic and asymptomatic dogs naturally infected with Leishmania chagasi. Am. J. Trop. Med. Hyg. 70, 618-624.
76. Sano, G., Hafalla, J. C., Morrot, A., Abe, R., Lafaille, J. J., and Zavala, F. (2001). Swift development of protective effector functions in naive CD8(+) T cells against malaria liver stages. J. Exp. Med. 194, 173-180.
77. Sbai, H., Mehta, A., and Degroot, A. S. (2001). Use of T cell epitopes for vaccine development. Curr. Drug Targets Infect. Disord. 1, 303-313.
78. Schirmbeck, R., Fissolo, N., Chaplin, P., and Reimann, J. (2003). Enhanced priming of multispecific, murine CD8+ T cell responses by DNA vaccines expressing stress protein-binding polytope peptides. J. Immunol. 171, 1240-1246.
79. Seyed, N., Zahedifard, F., Safaiyan, S., Gholami, E., Doustdari, F., Azadmanesh, K., Mirzaei, M., Saeedi Eslami, N., Khadem Sadegh, A., Eslami Far, A., Sharifi, I., and Rafati, S. (2011). In silico analysis of six known Leishmania major antigens and in vitro evaluation of specific epitopes eliciting HLA-A2 restricted CD8 T cell response. PLoS Negl. Trop. Dis. 5,e1295. doi:10.1371/journal.pntd.0001295.
80. Sharifi, I., Fekri, A. R., Aflatonian, M. R., Khamesipour, A., Nadim, A., Mousavi, M. R., Momeni, A. Z., Dowlati, Y., Godal, T., Zicker, F., Smith, P. G., and Modabber, F. (1998). Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 351, 1540-1543.
81. Skeiky, Y. A., Kennedy, M., Kaufman, D., Borges, M. M., Guderian, J. A., Scholler, J. K., Ovendale, P. J., Picha, K. S., Morrissey, P. J., Grabstein, K. H., Campos-Neto, A., and Reed, S. G. (1998). LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. J. Immunol. 161, 6171-6179.
82. Stager, S., Smith, D. F., and Kaye, P. M. (2000). Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J. Immunol. 165, 7064-7071.
83. Stefani, M. M., Muller, I., and Louis, J. A. (1994). Leishmania major-specific CD8+ T cells are inducers and targets of nitric oxide produced by parasitized macrophages. Eur. J. Immunol. 24, 746-752.
84. Stenger, S., Hanson, D. A., Teitelbaum, R., Dewan, P., Niazi, K. R., Froelich, C. J., Ganz, T., Thoma-Uszynski, S., Melian, A., Bogdan, C., Porcelli, S. A., Bloom, B. R., Krensky, A. M., and Modlin, R. L. (1998). An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 282, 121-125.
85. Stern, J. J., Oca, M. J., Rubin, B. Y., Anderson, S. L., and Murray, H. W. (1988). Role of L3T4+ and LyT-2+ cells in experimental visceral leishmaniasis. J. Immunol. 140, 3971-3977.
86. Sun, J., Madan, R., Karp, C. L., and Braciale, T. J. (2009). Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10. Nat. Med. 15, 277-284.
87. Titus, R. G., Gueiros-Filho, F. J., De Freitas, L. A., and Beverley, S. M. (1995). Development of a safe live Leishmania vaccine line by gene replacement. Proc. Natl. Acad. Sci. U.S.A. 92, 10267-10271.
88. Titus, R. G., Milon, G., Marchal, G., Vassalli, P., Cerottini, J. C., and Louis, J. A. (1987). Involvement of specific Lyt-2+ T cells in the immunological control of experimentally induced murine cutaneous leishmaniasis. Eur. J. Immunol. 17, 1429-1433.
89. Trandem, K., Zhao, J., Fleming, E., and Perlman, S. (2011). Highly activated cytotoxic CD8 T cells express protective IL-10 at the peak of coronavirusinduced encephalitis. J. Immunol. 186, 3642-3652.
90. Trapani, J. A., and Smyth, M. J. (2002). Functional significance of the perforin/granzyme cell death pathway. Nat. Rev. Immunol. 2, 735-747.
91. Tsagozis, P., Karagouni, E., and Dotsika, E. (2003). CD8(+) T cells with parasite-specific cytotoxic activity and a Tc1 profile of cytokine and chemokine secretion develop in experimental visceral leishmaniasis. Parasite Immunol. 25, 569-579.
92. Uzonna, J. E., Joyce, K. L., and Scott, P. (2004). Low dose Leishmania major promotes a transient T helper cell type 2 response that is downregulated by interferon gammaproducing CD8+ T cells. J. Exp. Med. 199, 1559-1566.
93. Velez, I. D., Gilchrist, K., Arbelaez, M. P., Rojas, C. A., Puerta, J. A., Antunes, C. M., Zicker, F., and Modabber, F. (2005). Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia. Trans. R. Soc. Trop. Med. Hyg. 99, 593-598.
94. Wang, Z. E., Reiner, S. L., Hatam, F., Heinzel, F. P., Bouvier, J., Turck, C. W., and Locksley, R. M. (1993). Targeted activation of CD8 cells and infection of beta 2-microglobulin-deficient mice fail to confirm a primary protective role for CD8 cells in experimental leishmaniasis. J. Immunol. 151, 2077-2086.
95. Webb, J. R., Campos-Neto, A., Ovendale, P. J., Martin, T. I., Stromberg, E. J., Badaro, R., and Reed, S. G. (1998). Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect. Immun. 66, 3279-3289.
96. Winau, F., Weber, S., Sad, S., De Diego, J., Hoops, S. L., Breiden, B., Sandhoff, K., Brinkmann, V., Kaufmann, S. H., and Schaible, U. E. (2006). Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis. Immunity 24, 105-117.
97. Woelbing, F., Kostka, S. L., Moelle, K., Belkaid, Y., Sunderkoetter, C., Verbeek, S., Waisman, A., Nigg, A. P., Knop, J., Udey, M. C., Von Stebut, E. (2006). Uptake of Leishmania major by dendritic cells is mediated by Fcgamma receptors and facilitates acquisition of protective immunity. J. Exp. Med. 203, 177-188.
98. Woodland, D. L., and Dutton, R. W. (2003). Heterogeneity of CD4(+) and CD8(+) T cells. Curr. Opin. Immunol. 15, 336-342.
99. Zhang, N., and Bevan, M. J. (2011). CD8(+) T cells: foot soldiers of the immune system. Immunity 35, 161-168.